News
The study by the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) research group (May 19 issue) 1 supports off-label use of bevacizumab (Avastin) for neovascular age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback